Gene Therapy Safety Drugs May Reduce Treatment Efficacy in Dravet Syndrome

References

1. 1.Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., ... & Gradinaru, V. (2016). Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nature Biotechnology, 34(2), 204-209. https://doi.org/10.1038/nbt.3440
2. 2.Dravet, C. (2011). The core Dravet syndrome phenotype. Epilepsia, 52(2), 3-9. https://doi.org/10.1111/j.1528-1167.2011.02994.x
3. 3.Hudry, E., & Vandenberghe, L. H. (2019). Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron, 101(5), 839-862. https://doi.org/10.1016/j.neuron.2019.02.017
4. 4.Kotterman, M. A., & Schaffer, D. V. (2014). Engineering adeno-associated viruses for clinical gene therapy. Nature Reviews Genetics, 15(7), 445-451. https://doi.org/10.1038/nrg3742
5. 5.Mast, J. (2026). Drug meant to make gene therapy safer may also make it less effective. STAT News. https://www.statnews.com/2026/05/13/encoded-therapeutics-dravet-syndrome-study-sirolimus-safety-tradeoff/
6. 6.Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., ... & Kaspar, B. K. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy. New England Journal of Medicine, 377(18), 1713-1722. https://doi.org/10.1056/NEJMoa1706198
7. 7.Mingozzi, F., & High, K. A. (2013). Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 122(1), 23-36. https://doi.org/10.1182/blood-2013-09-521831
8. 8.Ronzitti, G., Gross, D. A., & Mingozzi, F. (2020). Human immune responses to adeno-associated virus (AAV) vectors. Frontiers in Immunology, 11, 670. https://doi.org/10.3389/fimmu.2020.00670